Ekso Bionics Holdings, Inc. (EKSO)
- Previous Close
1.2900 - Open
1.3000 - Bid 1.2700 x 100
- Ask 1.3600 x 100
- Day's Range
1.2700 - 1.3300 - 52 Week Range
0.6200 - 3.1290 - Volume
29,644 - Avg. Volume
149,057 - Market Cap (intraday)
23.808M - Beta (5Y Monthly) 1.64
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9700 - Earnings Date Jul 25, 2024 - Jul 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.00
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.
www.eksobionics.comRecent News: EKSO
Performance Overview: EKSO
Trailing total returns as of 5/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EKSO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EKSO
Valuation Measures
Market Cap
23.81M
Enterprise Value
21.85M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.09
Price/Book (mrq)
1.69
Enterprise Value/Revenue
1.20
Enterprise Value/EBITDA
-1.66
Financial Highlights
Profitability and Income Statement
Profit Margin
-19.80%
Return on Assets (ttm)
-26.34%
Return on Equity (ttm)
-20.08%
Revenue (ttm)
17.91M
Net Income Avi to Common (ttm)
-3.55M
Diluted EPS (ttm)
-0.9700
Balance Sheet and Cash Flow
Total Cash (mrq)
8.8M
Total Debt/Equity (mrq)
48.69%
Levered Free Cash Flow (ttm)
--